MedTrace Logo

Novel Blood Biomarker for Peripheral Arterial Disease

NCT05596136 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 548

Last updated 2022-10-27

No results posted yet for this study

Summary

This study focuses on validating the clinical efficacy of a novel point of care diagnostic blood test for peripheral arterial disease (PAD) within a large, heterogeneous patient population. With support from CIHR, our aim is to overcome the knowledge-to-action gaps regarding inadequate and underutilized diagnostic modalities in patients with PAD who at high risk of cardiovascular (CV) events. We propose to ascertain the diagnostic accuracy of a blood-based marker for PAD by cross-validating it with the current gold-standard.

Conditions

  • Peripheral Arterial Disease

Interventions

DIAGNOSTIC_TEST

Artery Alert

A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Unity Health Toronto

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2025-08-31
Completion
2025-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596136 on ClinicalTrials.gov